#United States #Los Angeles #Armata Pharmaceuticals #AP-SA02 #bacteriophage

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update

Los Angeles, November 12, 2025 – Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a clinical-stage biotechnology company dedicated to developing high-purity, pathogen-specific bacteriophage therapeutics, recently released its financial results for the third quarter ended September 30, 2025. In addition, the company provided a corporate update detailing its latest advancements and future direction.

Positive Outcomes from Phase 2a Study

During this quarter, Armata highlighted the encouraging results from the Phase 2a "diSArm" study of its leading therapeutic candidate, AP-SA02. This bacteriophage treatment aims at addressing complicated Staphylococcus aureus (SAB) infections.

The results were presented as a late-breaking abstract on October 22 at IDWeek 2025 in Atlanta, showcasing a significant improvement in cure rates when AP-SA02 was administered alongside the Best Available Antibiotic Therapy (BAT). Notably, patients receiving AP-SA02 exhibited a cure rate that was both higher and achieved earlier compared to those receiving BAT alone. At twelve days, the AP-SA02 treatment group displayed a 100% response rate without relapse, contrasting sharply with about 25% of the placebo group experiencing recurrence.

Furthermore, AP-SA02 has shown favorable safety and tolerability across both methicillin-resistant and methicillin-sensitive S. aureus, indicating a potentially robust new treatment option for these challenging infections. The treatment correlated with reduced markers of inflammation, shorter hospital stays, and more rapid normalization of clinical indicators such as C-reactive protein.

Manufacturing Facility Commissioned

Armata has officially commissioned its state-of-the-art current Good Manufacturing Practice (cGMP) facility in Los Angeles. This facility spans 56,000 square feet, inclusive of clean rooms and quality control labs, and is fully operational for scaling production necessary for late-stage clinical trials and potential commercialization.

In light of the growing antimicrobial resistance crisis, this facility supports the U.S. government’s objective of securing the supply chain for essential medications. Armata’s commitment to domestically-based manufacturing aligns with efforts to provide critical resources in healthcare during times of need.

Financial Update

The company reported a grant and award revenue of $1.2 million for the three months ending September 30, 2025, compared to $3.0 million during the same timeframe last year. Research and development costs also fell to approximately $5.8 million, a decrease from $9.5 million in the previous year. These reductions reflect completed clinical trials and operational efficiencies while maintaining support for key development projects.

The total general and administrative expenses remained stable at around $3.1 million. Unfortunately, the company encountered a loss from operations amounting to $7.8 million, an improvement over the prior year’s loss of $9.8 million.

As of September 30, 2025, Armata held $14.8 million in cash and cash equivalents. This is a positive increase compared to $9.3 million recorded at the end of 2024, indicating better liquidity and operational resilience.

Future Outlook

Looking ahead, Armata is preparing to advance AP-SA02 into late-stage clinical development, pending regulatory review by the U.S. Food and Drug Administration. The company is optimistic about its pathway to potentially establish this treatment as a new standard of care for complicated SAB.

Dr. Deborah Birx, CEO of Armata, emphasized the importance of the compelling data from the recent studies, suggesting that this presents strong justification for moving forward with the next phases of clinical trials. With advancements in phage-based therapeutics, Armata is positioning itself to provide new solutions for patients with significant unmet medical needs, thus promising long-term value creation for its shareholders.

Conclusion

Armata Pharmaceuticals stands at the forefront of innovative solutions to combat bacterial infections through its development of bacteriophage therapeutics. With a well-defined path forward, including the commissioning of its manufacturing facility and promising clinical data, Armata remains committed to addressing the critical health issue of antibiotic resistance as it flourishes in an ever-evolving medical landscape.